A team at the University of Chicago is reimagining diagnostics with an unexpected material—air. Their invention, called ABLE (Airborne Biomarker Localization Engine), does something astonishingly simple yet revolutionary: it turns breath into liquid. Not metaphorically, but quite literally.

The Problem with Blood

There’s a reason why blood dominates diagnostics: it’s rich with molecular information. Glucose levels, hormones, antibodies, inflammatory markers—all float conveniently in our veins. Yet extracting that data involves discomfort, infrastructure, and time.

For newborns in neonatal intensive care, for instance, even a tiny blood draw can be a significant medical event. And for diabetics, frequent finger sticks are just part of daily life.

While non-invasive sensors have gained traction, most—like pulse oximeters or smartwatches—focus on surface-level vitals. Going deeper has always meant going under the skin. Until now.

Here’s the catch: air isn’t dense. Molecules in your breath are scattered—millions of times more diluted than in blood. Detecting them reliably has long required bulky lab equipment like mass spectrometers. That’s hardly feasible at your bedside or in a public restroom.

ABLE sidesteps this entirely by condensing the air into droplets, effectively “squeezing” those sparse molecules into a form that can be analyzed with standard liquid-based tools. It’s like collecting morning dew and finding in it the secrets of your metabolism.

The device contains a pump, a humidifier, and a tiny refrigeration unit. These components work together to cool humidified air rapidly, forming droplets that slide down a silicon-spiked surface. The result? A miniature vial of your breath, ready for analysis.

How ABLE Works in Real Life

In one quirky early test, lead researcher Jingcheng Ma blew vaporized coffee into the device. Not only did it work—the scent of coffee lingered in the condensed liquid—it also confirmed ABLE’s ability to capture volatile molecules. That paved the way for medical tests involving more complex molecules like glucose, markers of bacterial infection, and even signs of inflammation related to gut health.

In hospitals, ABLE could be a game-changer. Imagine detecting airborne pathogens in waiting rooms before they cause outbreaks. Or checking an infant’s health via breath instead of blood. It’s already been shown to capture signs of E. coli and inflammation in animal studies.

The device’s core innovation—its slippery condensation surface—isn’t entirely man-made.

It draws inspiration from organisms that have mastered water collection, like desert beetles that pull moisture from thin fog, or lotus leaves that remain dry despite constant contact with water. Their secret lies in super hydrophobic textures—tiny ridges and valleys that repel water.

The ABLE team mimicked this strategy using microscopic silicon spikes, about 1/200th the width of a human hair. This design doesn’t just help collect droplets; it helps preserve the integrity of the biomarkers within them. Think of it as designing a racetrack for molecules, with no puddles or potholes to interfere.

The Road Ahead: Smaller, Smarter, and Everywhere

While today’s ABLE device is portable, the goal is wearability. A miniaturized version could monitor your health as passively as a fitness tracker, checking for early signs of respiratory infections, inflammation, or even metabolic changes—all by simply breathing.

Researchers also plan to expand its capabilities beyond healthcare. Food spoilage detection, pollution tracking, even biosecurity at airports could benefit from this tech.

Yet challenges remain. Current models still capture only a fraction of ambient moisture, and the water-repelling coating may degrade over time. But as with any transformative tool, refinement is part of the journey.

[Source: 1,2]

The post University of Chicago’s New Device Could Replace Needles in Medical Diagnostics appeared first on Medical Journal Daily.

The breakthrough, led by Professor Per-Ola Carlsson, offers hope for a safer, more sustainable therapy that targets the root cause of the disease.

What’s Changed—and Why It Matters

Transplanting insulin-producing cells isn’t new. The problem has always been the immune system: it sees donor cells as foreign invaders and attacks. Until now, the only way around this was lifelong immunosuppression—medications that dampen the immune response but increase risks for infections, cancers, and other complications.

Carlsson and his team have flipped the script. Instead of weakening the immune system, they’ve engineered the donor cells to avoid triggering it altogether. These modified cells are engineered to be “hypoimmune,” meaning they don’t trigger the body’s usual immune alarms. Instead of being flagged and attacked, they remain undetected, allowing them to function without interference.

It’s a clever reframe of the problem, shifting the focus from managing the immune response to eliminating the cause of it.

Inside the Breakthrough: How the Cells Stay Hidden

The modified cells have been altered in three key genetic ways, allowing them to operate “under the radar,” as Carlsson puts it. The early results are promising. Since the trial began in December, the transplanted cells have remained active and stable, continuing to produce insulin with no evidence of immune rejection.

That’s a stark contrast to earlier efforts, where conventional donor cells would be attacked and fail within weeks. The genetic modifications appear to prevent that decline, marking a significant advancement in cell-based therapies for diabetes.

From Trial to Treatment of Type 1 Diabetes Cell Transplant

This initial study is designed to track long-term safety over a 15-year period. But more trials could begin sooner, especially as the team works to apply the same genetic tweaks to stem cells. That step would open the door to scalable production—allowing millions of identical, hypoimmune insulin-producing cells to be manufactured for clinical use.

If successful, this approach could do more than just improve treatment—it could pave the way toward an actual cure. Carlsson believes these engineered stem cells could eventually become the foundation of a pharmaceutical product capable of replacing insulin injections entirely.

In the world of diabetes care, where day-to-day management has long been the norm, this study offers a radical alternative: reprogramming the body to do what it once could—without compromise, and without fear of immune rejection.

[Source: 1,2]

The post New Diabetes Treatment Uses Genetically Modified Cells to Avoid Immune Rejection appeared first on Medical Journal Daily.

The development of this 3-minute heart restart system was spurred by the tragic assassination of former Japanese Prime Minister Shinzo Abe in July 2022. Abe was fatally shot during a political event, and the damage to his heart from the bullet was a key factor in his death. The incident underscored the urgent need for faster and more effective medical interventions in similar emergencies.

Associate Professor Yasuyuki Shiraishi and his team at Tohoku University’s Institute of Development, Aging, and Cancer spearheaded the project. The system they developed involves a meticulously coordinated sequence of procedures aimed at quickly resuming blood circulation. It includes securing the patient’s airway, performing an emergency thoracotomy to access the chest cavity, controlling bleeding, and administering transfusions.

A key component of the system is the use of an artificial pump. During the procedure, the left ventricle of the heart is punctured to attach this pump, which is then connected to the femoral artery to restore blood flow. In cases where connecting through the femoral artery is not feasible due to the injury’s location, alternative routes can be used. Additionally, the system can incorporate an artificial lung if the patient has sustained lung injuries.

The researchers emphasize that the critical window to prevent brain death following the cessation of blood circulation is extremely narrow—only three minutes. Traditional methods often fall short in such urgent scenarios, making this new system particularly valuable. The ability to resume circulation within this short timeframe could significantly enhance survival rates and outcomes for patients with severe injuries.

The team at Tohoku University is now focused on further developing and demonstrating the system. They believe that its implementation could lead to a substantial increase in the number of lives saved during emergencies. This advancement represents a significant step forward in emergency medical care, offering new hope for rapid and effective responses to life-threatening injuries.

References:

Japan: 3-minute heart restart system for emergencies developed by scientists.” Available from: https://www.japantimes.co.jp/news/2023/07/17/national/heart-restart-system

The post Japan: 3-Minute Heart Restart System for Emergencies Developed by Scientists appeared first on Medical Journal Daily.